

Manali Kamdar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11465040/publications.pdf>

Version: 2024-02-01

41
papers

1,513
citations

516710

16
h-index

330143

37
g-index

42
all docs

42
docs citations

42
times ranked

2391
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	1.4	50
2	Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. <i>Leukemia</i> , 2022, 36, 1171-1175.	7.2	72
3	A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2757-2762.	5.2	19
4	Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. <i>Blood Advances</i> , 2022, 6, 4553-4557.	5.2	22
5	Abstract CT522: Feasibility and safety of a novel CD19 CAR T cell therapy in adults with R/R B-NHL. <i>Cancer Research</i> , 2022, 82, CT522-CT522.	0.9	0
6	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
7	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
8	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
9	COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. <i>Blood</i> , 2021, 138, 1768-1773.	1.4	53
10	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
11	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
12	High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers. <i>Blood</i> , 2021, 138, 455-455.	1.4	4
13	Addressing a New Challenge in Chronic Lymphocytic Leukemia: Outcomes of Therapies after Exposure to Both a Covalent Bruton's Tyrosine Kinase Inhibitor and Venetoclax. <i>Blood</i> , 2021, 138, 2628-2628.	1.4	10
14	A Multi-Center Retrospective Study of Polatuzumab for Patients with Large B-Cell Lymphoma Relapsed after Standard of Care CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2495-2495.	1.4	1
15	Improved Quality of Life (QOL) with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Compared with Standard of Care (SOC) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 3 Transform Study. <i>Blood</i> , 2021, 138, 3845-3845.	1.4	9
16	A Pilot Study Using Nivolumab in Combination with Standard of Care Chemotherapy in Newly Diagnosed Peripheral T-Cell Lymphomas. <i>Blood</i> , 2021, 138, 2444-2444.	1.4	1
17	Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis. <i>Cancer</i> , 2020, 126, 189-201.	4.1	17
18	Evaluating Novel PET-CT Functional Parameters TLG and TMTV in Differentiating Low-grade Versus Grade 3A Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 39-46.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Outcomes of COVID-19 in patients with CLL: a multicenter international experience. <i>Blood</i> , 2020, 136, 1134-1143.	1.4	248
20	Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant. <i>Blood Advances</i> , 2020, 4, 2227-2235.	5.2	36
21	Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naïve chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1278-1291.	13.7	393
22	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. <i>Blood</i> , 2020, 136, 27-28.	1.4	9
23	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
24	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
25	Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study. <i>Blood</i> , 2020, 136, 30-31.	1.4	1
26	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	5.2	18
27	Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 1234-1243.	1.3	11
28	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	1.4	3
29	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	1.4	9
30	Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1671-1677.	2.0	13
31	Management of Non-Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. <i>Current Treatment Options in Oncology</i> , 2018, 19, 33.	3.0	8
32	Positron Emission Tomography-based Analysis Can Accurately Predict Bone Marrow Involvement With Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 731-736.	0.4	5
33	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
34	Addition of Rituximab to High-Dose Methotrexate Regimens Improves Complete Response Rates and Median Overall Survival in Non-Germinal Center Primary CNS Lymphoma. <i>Blood</i> , 2018, 132, 4217-4217.	1.4	0
35	PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent CVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
36	Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 1267-1268.	4.1	0

#	ARTICLE	IF	CITATIONS
37	PD-1 Blockade in Mediastinal Gray-Zone Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 89-91.	27.0	52
38	Improved survival with combined modality therapy in the modern era for primary mediastinal <sc>B</sc>-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 476-480.	4.1	25
39	Improved Survival With Radiation Therapy in Stage I-II Primary Mediastinal B Cell Lymphoma: A Surveillance, Epidemiology, and End Results Database Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 126-132.	0.8	18
40	Checkpoint Blockade for Treatment of Relapsed Lymphoma Following Allogeneic Hematopoietic Cell Transplant: Use May be Complicated By Onset of Severe Acute Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 1163-1163.	1.4	7
41	Post-Transplant Diffuse Large B Cell Lymphoma with Non Germinal Center B-Cell Subtype Frequently Lacks Programmed Cell Death Ligand (PD-L1) Overexpression Which May Influence Overall Outcomes. <i>Blood</i> , 2016, 128, 3054-3054.	1.4	0